Besides massive expression in inflammatory pleural effusions, inflammatory markers are also present in cancer-induced pleural effusions. Recent advances in cancer biology point to a role of inflammatory signaling in cancer and encourage reconsidering the diagnostic and prognostic value of inflammatory markers. Here an attempt was made to relate protein levels of inflammatory markers to underlying malignant processes in the pleural space.
Pleural effusions from lung cancer patients (n=116) were subjected to a multifactorial analysis covering 13 inflammatory markers. The composition of tumor-associated effusions was compared with that of parainflammatory pleural effusions (n=30), transudates (n=18), and serum values, and evaluated in relation to cancer origin, histology, cytology, pleural involvement, treatment history, and survival time.
Inflammatory markers were significantly expressed in pleural effusions of paraneoplastic origin when compared to transudates and most serum levels. Values in pleura-invading and metastatic tumor-associated effusions were typically higher than those of other tumors. Many markers correlated negatively with survival, most prominently IL-8 (r=–0.36, p=0.001) and VEGF (r=–0.35, p=0.001).
It appears that most inflammatory markers are highly expressed in tumor-associated pleural effusions, reflecting to some extent tumor origin and localization. Despite the lower efficacy of inflammatory markers in the differentiation between exudative pleural effusions, some inflammatory markers may represent potential prognostic markers of malignant processes in the pleural space.
LightR.W.Disorders of the pleura, mediastinum, diaphragm, and chest wall. In: KasperD.L., BraunwaldE., HauserS., LongoD., JamesonJ.L., FauciA.S., eds. Harrison's principles of internal medicine, 16th Ed.New York: McGraw-Hill Companies, Inc.2005; 1565–9.
2.
MelisM., PaceE., SienaL.Biologically active intercellular adhesion molecule-1 is shed as dimers by a regulated mechanism in the inflamed pleural space.Am J Respir Crit Care Med2003; 167: 1131–8.
3.
VidrialesC.J.L., AntequeraA.C.Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions.Eur J Med1992; 1: 201–7.
4.
Yilmaz TurayU., YildrimZ., TurkozY.Use of pleural fluid C-reactive protein in diagnosis of pleural effusions.Respir Med2000; 94: 432–5.
5.
Garcia-PachonE., LlorcaI.Diagnostic value of C-reactive protein in exudative pleural effusions.Eur J Intern Med2002; 13: 246–9.
6.
HuaC-C, ChangL-C, ChenY-C, ChangS-C. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.Chest1999; 116: 1292–6.
YokoyamaA., MaruyamaM., ItoM., KohnoN., HiwadaK., YanoS.Interleukin 6 activity in pleural effusion. Its diagnostic value and thrombopoietic activity.Chest1992; 102: 1055–9.
9.
HoheiselG., IzbickiG., RothM.Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy.Respir Med1998; 92: 14–7.
10.
HoheiselG., IzbickiG., RothM.Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy.Respiration1998; 65: 183–6.
11.
AlexandrakisM.G., CoulocheriS.A., BourosD.Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions.Anticancer Res1999; 19: 3607–12.
12.
XirouchakiN., TzanakisN., BourosD.Diagnostic value of interleukin-1, interleukin-6, and tumor necrosis factor in pleural effusion.Chest2002; 121: 815–20.
13.
ChenY.M., YangW.K., Whang-PengJ., KuoB.I., PerngR.P.Elevation of interleukin-10 levels in malignant pleural effusion.Chest1996; 110: 433–6.
14.
YanagawaH., TakeuchiE., SuzukiY., OhmotoY., BandoH., SoneS.Presence and potent immunosuppresive role of interleukin –10 in malignant pleural effusion due to lung cancer.Cancer Lett1999; 136: 27–32.
15.
ChenY.M., YangW.K., Whang-PengJ., TsaiC.M., PerngR.P.An analysis of cytokine status in the serum and effusions of patients with tuberculosis and lung cancer.Lung Cancer2001; 31: 25–30.
16.
AntonyV.B., GoodbeyS.W., KunkelS.L.Recruitment of inflammatory cells to the pleural space. Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids.J Immunol1993; 151: 7216–23.
17.
KiropoulosT.S., KostikasK., OikonomidiS.Acute phase markers for the differentiation of infectious and malignant pleural effusions.Respir Med2007; 101: 910–8.
18.
SackU., HoffmannM., ZhaoX.J.Vascular endothelial growth factor in pleural effusions of different origin.Eur Respir J2005; 25: 600–4.
19.
MomiH., MatsuyamaW., InoueK.Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions.Respir Med2002; 96: 817–22.
20.
HamzaouiA., HamzaouiK., KahanA., ChabbouA.Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin in patients with tuberculous pleuritis.Mediators Inflamm1996; 5: 276–9.
21.
KalomenidisI., MohamedK.H., LaneK.B.Pleural fluid levels of vascular cell adhesion molecule-1 are elevated in eosinophilic pleural effusions.Chest2003; 124: 159–66.
22.
AlegreJ., JufresaJ., AlemánC.Pleural fluid myeloperoxidase as a marker of infectious pleural effusions.Eur J Intern Med2001; 12: 357–62.
23.
EickelbergO., SommerfeldC.O., WyserC., TammM., ReichenbergerF.MMP and TIMP expression pattern in pleural effusions of different origins.Am J Respir Crit Care Med1997; 156: 1987–92.
24.
KotyzaJ., HavelD., PesekM., LosanF.Expression of metalloproteinases MMP-2 and MMP-9 in malignant and non-malignant pleural effusions.Stud Pneumol Phthiseol2002; 62: 64–70.
25.
Van KempenL.C.L., RuiterD.J., van MuijenG.N.P., CoussensL.M.The tumor microenvironment: a critical determinant of neoplastic evolution.Eur J Cell Biol2003; 82: 539–48.
26.
LawrenceT., HagemannT., BalkwillF.Sex, cytokines, and cancer.Science2007; 317: 51–2.
27.
CoussensL.M., WerbZ.Inflammation and cancer.Nature2002; 420: 860–7.
28.
PiancatelliD., RomanoP., SebastianiP., AdornoD., CascianniC.U.Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression.J Immunother1999; 22: 25–32.
29.
NagtegaalI.D., MarijnenC.A., KranenbargE.K.Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study.BMC Cancer2001; 1: 7.
30.
CelisJ.E., GromovP., CabezónT.Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment.Mol Cell Proteomics2004; 3: 327–44.
31.
SzlosarekP., BalkwillF.The inflammatory cytokine network of epithelial cancer: therapeutic implications.Novartis Found Symp2004; 256: 237–40.
32.
StathopoulosG.T., ZhuZ., EverhartM.B.Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.Am J Respir Cell Mol Biol2006; 34: 142–50.
VrzalovaJ., PrazakovaM., NovotnyZ., TopolcanO., CasovaM., HolubecL.Jr.. Test of ovarian cancer multiplex xMAP technology panel.Anticancer Res2009; 29: 573–6.
35.
AlexandrakisM.G., CoulocheriS.A., BourosD.Significance of alpha-2-macroglobulin, alpha-1-acid glycoprotein, and C-reactive protein in pleural effusion differentiation.Respiration2000; 67: 30–5.
36.
Castano VidrialesJ.L., Amores AntequeraC.Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions.Eur J Med1992; 1: 201–7.
37.
StamenkovicI.Matrix metalloproteinases in tumor invasion and metastasis.Semin Cancer Biol2000; 10: 415–33.
38.
PollardJ.W.Tumour-educated macrophages promote tumour progression and metastasis.Nature Rev2004; 4: 71–8.
39.
KotyzaJ., PešekM., PuzmanP., HavelD.Progelatinase B/proMMP-9 as a marker of pleural inflammation.Exp Lung Res2004; 30: 297–309.
40.
JungK., LeinM., LaubeC., LichtinghagenR.Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.Clin Chim Acta2002; 325: 183–6.
41.
WertherK., ChristensenI.J., NielsenH.J.Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.Br J Cancer2002; 86: 417–23.
42.
TeradaH., UranoT., KonnoH.Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.Eur Surg Res2005; 37: 166–72.
43.
PeraM., NelsonH., RajkumarS.V., Young-FadokT.M., BurgartL.J.Influence of postoperative acute-phase response on angiogenesis and tumor growth: open vs. laparoscopic-assisted surgery in mice.J Gastrointest Surg2003; 7: 783–90.
44.
YanoS., SinoharaH., HerbstR.S.Production of experimental malignant pleural effusion is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.Am J Pathol2000; 157: 1893–903.
45.
WrightJ.G., ChristmanJ.W.The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy.Am J Respir Med2003; 2: 211–9.
46.
LuoJ-L, TanW., RiconoJ.M.Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.Nature2007; 446: 690–4.
47.
FutakuchiM., OgawaK., TamanoS., TakahashiS., ShiraiT.Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma.Cancer Sci2004; 95: 18–24.
